Dores GM - Search Results

1

Adverse Events Associated with Use of Digoxin Immune Fab Reported to the US Food and Drug Administration Adverse Event Reporting System, 1986-2019.

Wei S, Niu MT, Dores GM. Wei S, et al. Among authors: dores gm. Drugs Real World Outcomes. 2021 Jun;8(2):253-262. doi: 10.1007/s40801-021-00242-x. Epub 2021 Mar 15. Drugs Real World Outcomes. 2021. PMID: 33721285 Free PMC article.

2

Trends in risk for therapy-related myelodysplastic syndrome/acute myeloid leukemia after initial chemo/immunotherapy for common and rare lymphoid neoplasms, 2000-2018.

Morton LM, Curtis RE, Linet MS, Schonfeld SJ, Advani PG, Dalal NH, Sasse EC, Dores GM. Morton LM, et al. Among authors: dores gm. EClinicalMedicine. 2023 Jul 5;61:102060. doi: 10.1016/j.eclinm.2023.102060. eCollection 2023 Jul. EClinicalMedicine. 2023. PMID: 37457112 Free PMC article.

3

Risks of therapy-related hematologic neoplasms beyond myelodysplastic syndromes and acute myeloid leukemia.

Dores GM, Linet MS, Curtis RE, Morton LM. Dores GM, et al. Blood. 2023 Feb 23;141(8):951-955. doi: 10.1182/blood.2022018051. Blood. 2023. PMID: 36379026 Free PMC article. No abstract available.

4

Adverse Events Associated With the Use of Sipuleucel-T Reported to the US Food and Drug Administration's Adverse Event Reporting System, 2010-2017.

Dores GM, Bryant-Genevier M, Perez-Vilar S. Dores GM, et al. JAMA Netw Open. 2019 Aug 2;2(8):e199249. doi: 10.1001/jamanetworkopen.2019.9249. JAMA Netw Open. 2019. PMID: 31411714 Free PMC article.

5

Case series of reports of pruritus and sipuleucel-T submitted to the Food and Drug Administration Adverse Event Reporting System.

Dores GM, Perez-Vilar S, Niu MT. Dores GM, et al. J Pharm Health Care Sci. 2019 Dec 19;5:27. doi: 10.1186/s40780-019-0156-0. eCollection 2019. J Pharm Health Care Sci. 2019. PMID: 31890238 Free PMC article.

6

Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data.

Dores GM, Niu MT, Izurieta HS. Dores GM, et al. Cancer. 2020 Jun 15;126(12):2934-2935. doi: 10.1002/cncr.32786. Epub 2020 Mar 10. Cancer. 2020. PMID: 32154909 Free article. No abstract available.

7

Safety Surveillance of Bivalent Meningococcal Group B Vaccine, Vaccine Adverse Event Reporting System, 2014-2018.

Duffy J, Marquez P, Dores GM, Ng C, Su J, Cano M, Perez-Vilar S. Duffy J, et al. Among authors: dores gm. Open Forum Infect Dis. 2020 Oct 27;7(12):ofaa516. doi: 10.1093/ofid/ofaa516. eCollection 2020 Dec. Open Forum Infect Dis. 2020. PMID: 33324721 Free PMC article.

8

Adverse events reported to the U.S. Food and Drug Administration Adverse Event Reporting System for tisagenlecleucel.

Dores GM, Jason C, Niu MT, Perez-Vilar S. Dores GM, et al. Am J Hematol. 2021 Sep 1;96(9):1087-1100. doi: 10.1002/ajh.26246. Epub 2021 Jun 11. Am J Hematol. 2021. PMID: 34050534 Free article.

9

Safety surveillance of meningococcal group B vaccine (Bexsero®), Vaccine Adverse Event Reporting System, 2015-2018.

Perez-Vilar S, Dores GM, Marquez PL, Ng CS, Cano MV, Rastogi A, Lee L, Su JR, Duffy J. Perez-Vilar S, et al. Among authors: dores gm. Vaccine. 2022 Jan 21;40(2):247-254. doi: 10.1016/j.vaccine.2021.11.071. Epub 2021 Dec 7. Vaccine. 2022. PMID: 34887130 Free PMC article.

10

Post-licensure surveillance of trivalent adjuvanted influenza vaccine (aIIV3; Fluad), Vaccine Adverse Event Reporting System (VAERS), United States, July 2016-June 2018.

Haber P, Moro PL, Ng C, Dores GM, Lewis P, Cano M. Haber P, et al. Among authors: dores gm. Vaccine. 2019 Mar 7;37(11):1516-1520. doi: 10.1016/j.vaccine.2019.01.052. Epub 2019 Feb 7. Vaccine. 2019. PMID: 30739795

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

97 results

Search Page

Filters